---
reference_id: clinicaltrials:NCT00000001
title: A Phase III Study of Drug X for Treatment of Disease Y
content_type: summary
---

# A Phase III Study of Drug X for Treatment of Disease Y

## Content

This study evaluates the efficacy and safety of Drug X in patients with Disease Y. The primary endpoint is overall survival at 12 months. Secondary endpoints include progression-free survival, quality of life measures, and adverse event profiles. Participants will be randomized 1:1 to receive either Drug X or placebo in addition to standard of care treatment.
